Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
about
MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerTargeted Therapies in Triple-Negative Breast CancerTriple negative breast cancer: looking for the missing link between biology and treatmentsPARP inhibitors in the management of breast cancer: current data and future prospectsMicroRNAs and triple negative breast cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyProfile of neratinib and its potential in the treatment of breast cancerQuantification of HER family receptors in breast cancerNear Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light RegimenTBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerA perspective on anti-EGFR therapies targeting triple-negative breast cancerFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesCisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast CancerAptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cellsPrognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.ICAM-1 as a molecular target for triple negative breast cancerIs the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisSelecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.Subtyping of triple-negative breast cancer: implications for therapyTriple-negative breast cancer: new perspectives for targeted therapies.Basal-like and triple-negative breast cancers: searching for positives among many negativesIncidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical modelTargeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.Prognostic value of ERBB4 expression in patients with triple negative breast cancer
P2860
Q26775086-80CF172C-A1CF-4617-983B-AEBE18BF8E14Q26777736-C62B8130-01AD-4825-98C6-A9F58B4F1E2EQ26783122-DE5D43E7-1B14-47A2-9CEF-A8A898A3AEA1Q26798352-2112BB99-997E-43C9-9D5F-E8B4FAAD2B8DQ26862716-FA2DE706-E886-4C1F-A151-5860C909D9ADQ26993238-5CD25D89-EE64-412F-8D55-D9BDD4D93F8CQ27012540-AEB260C7-2343-40DE-B515-1ACEA336E92BQ27015506-3019D67D-381F-4786-8839-73BAE5297E0FQ27320934-7AD18358-1E76-48BB-B716-11C4A7543CE7Q27853147-5669264A-415E-4158-AB53-DA03945E568DQ28069867-0373FE89-1DF6-4EDF-BB14-EB25049CB081Q28077347-BF53FC40-7270-4F16-9A21-84B4ADA33B80Q28080469-68C00D7B-63CD-47B9-996C-86A936A99AF7Q33415281-DEF50487-58C6-4C31-85C0-FBCA2FFE2DA0Q33420154-5407CE1E-7EBB-4E1B-8BB9-E4F0F1140982Q33422448-7603DC55-40CC-4663-A090-380B25E0F396Q33576608-A102A731-2470-44AD-84FE-66EB9516B92CQ33582972-8650876D-7521-4A48-8989-7F0D59D5A1FBQ33591876-14FD4829-91A0-45C0-BED1-C943158341CEQ33593900-F19A5396-7E32-4611-BE1C-1BF1CE27CA47Q33646271-1BAB58A6-FE77-40F0-819A-FEC561B001E4Q33769821-FBFC61ED-E7B3-4B09-8FE7-06C865767924Q33770856-19268E78-07AD-4B6F-A755-FF62B6E05589Q33874621-7A3343A5-D483-4FEB-990F-38863A91025EQ33954557-D2AF7A43-BC36-4BE7-811C-BCEE05A8B2F4Q34383956-E4265388-BFA8-44B5-BCD0-2D8175AC675EQ34476337-69748703-A72C-4711-8FFA-1DA83281EFAFQ34537664-9069C109-7042-4389-9F9F-FC64BE10281EQ34658278-2E2FD316-CD33-4515-BBAB-4C52E0302CDDQ34734477-01F029BF-7B39-4CA8-8D56-641F0332AE84Q35001758-1D5B8F12-38CD-4912-87C3-7F68FC17B620Q35005793-3C73C0C8-E2EC-48C2-A2FF-6C935135DE95Q35060785-8715C966-8284-4BA1-9967-E60848DD37ACQ35313206-6ADBD42B-1B71-4BA2-BFDE-E9BD29B53E8FQ35612933-572609E3-70DE-4F22-BC7A-59404DB33D89Q35625440-9EC0C97A-459B-4139-91FC-D7ED884D619CQ35652853-5193C013-5135-4B11-B1A2-42E8DDBA97BAQ35742544-88B650B8-6858-47C3-B03D-0DE6445CEA30Q35853834-707E7D27-3EF1-4156-BADC-166ED983D26FQ35933318-BAF0B7EE-B02C-4123-B543-DBD725317F06
P2860
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Randomized phase II study of t ...... triple-negative breast cancer.
@en
Randomized phase II study of t ...... triple-negative breast cancer.
@nl
type
label
Randomized phase II study of t ...... triple-negative breast cancer.
@en
Randomized phase II study of t ...... triple-negative breast cancer.
@nl
prefLabel
Randomized phase II study of t ...... triple-negative breast cancer.
@en
Randomized phase II study of t ...... triple-negative breast cancer.
@nl
P2093
P2860
P921
P356
P1476
Randomized phase II study of t ...... triple-negative breast cancer.
@en
P2093
Ahmad Awada
Angela Zubel
António Pêgo
Arlene Chan
Bella Kaufman
Eva Maria Ciruelos Gil
Helena Melezínková
Jean-Charles Goeminne
José Baselga
Jutta Groos
P2860
P304
P356
10.1200/JCO.2012.46.2408
P407
P577
2013-06-03T00:00:00Z